Contemporary HIV Treatment and Prevention 2022

Major inequities in PrEP uptake, adherence, and persistence have been seen in Black and Hispanic/Latinx people, cisgender women, transgender women, adolescents, and people who inject drugs. Here’s how we can address them.

Neha Pandit, PharmD, AAHIVP, BCPS Released: December 2, 2022

We now have long-acting injectable options for both the treatment and prevention of HIV, with more to learn as we incorporate this exciting new paradigm. Here are my thoughts on key differences among available HIV prevention medications and the potential role of individual pharmacokinetic variability in the efficacy of long-acting options for prevention and treatment.

Melanie Nicol, PharmD, PhD Released: December 30, 2022

Finding an appropriate and effective therapeutic regimen for treatment-experienced people with HIV can be challenging. Read my summary of the current options available for managing these complex cases.

Rodrigo Burgos, PharmD, MPH Released: February 6, 2023